A melanocortin agonist that acts on the nervous system rather than the vasculature — the active ingredient of an approved therapeutic.
01Overview
PT-141 (bremelanotide) is a cyclic peptide melanocortin-receptor agonist. It is the active ingredient of Vyleesi, an FDA-approved medicine, so it is a clinically characterized molecule rather than a purely investigational one.
It is distinctive for acting centrally on desire pathways rather than on blood flow like PDE5 inhibitors.
02Mechanism
- Activates melanocortin receptors (notably MC4R) in the central nervous system.
- Influences dopaminergic pathways associated with sexual desire.
- Acts upstream of the vascular mechanisms targeted by other agents.
03Research uses
- Central desire-pathway research
- Melanocortin-signaling studies
- Neuroendocrine-behavior models
04Key findings
- Clinically evaluated and approved for its specific indication.
- Transient flushing and nausea are commonly reported handling considerations.
- Effects are behaviorally rather than purely vascularly mediated.
05Handling & reconstitution
- Supplied lyophilized as a white powder.
- Reconstitute with bacteriostatic water; swirl gently.
- Store cold and dark; refrigerate reconstituted solution.
All information on peptek is aggregated from public sources for research and educational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease. Peptide products referenced here are not for human consumption of any kind. Always consult a qualified healthcare professional before beginning any research protocol.